Kir6.2 mutations causing neonatal diabetes provide new insights into Kir6.2-SUR1 interactions

被引:52
|
作者
Tammaro, P
Girard, C
Molnes, J
Njolstad, PR
Ashcroft, FM
机构
[1] Univ Oxford, Physiol Lab, Oxford OX1 3PT, England
[2] Univ Bergen, Sect Pediat, Dept Clin Med, Bergen, Norway
[3] Haukeland Hosp, Dept Pediat, N-5021 Bergen, Norway
来源
EMBO JOURNAL | 2005年 / 24卷 / 13期
基金
英国惠康基金;
关键词
diabetes; K-ATP channel; Kir6.2; SUR1;
D O I
10.1038/sj.emboj.7600715
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
ATP-sensitive K+ (K-ATP) channels, comprised of pore-forming Kir6.2 and regulatory SUR1 subunits, play a critical role in regulating insulin secretion. Binding of ATP to Kir6.2 inhibits, whereas interaction of MgATP with SUR1 activates, KATP channels. We tested the functional effects of two Kir6.2 mutations (Y330C, F333I) that cause permanent neonatal diabetes mellitus, by heterologous expression in Xenopus oocytes. Both mutations reduced ATP inhibition and increased whole-cell currents, which in pancreatic beta-cells is expected to reduce insulin secretion and precipitate diabetes. The Y330C mutation reduced ATP inhibition both directly, by impairing ATP binding (and/or transduction), and indirectly, by stabilizing the intrinsic open state of the channel. The F333I mutation altered ATP binding/transduction directly. Both mutations also altered Kir6.2/SUR1 interactions, enhancing the stimulatory effect of MgATP ( which is mediated via SUR1). This effect was particularly dramatic for the Kir6.2-F333I mutation, and was abolished by SUR1 mutations that prevent MgATP binding/hydrolysis. Further analysis of F333I heterozygous channels indicated that at least three SUR1 must bind/hydrolyse MgATP to open the mutant KATP channel.
引用
收藏
页码:2318 / 2330
页数:13
相关论文
共 50 条
  • [11] Kir6.2, diabetes and neurology: new insights, new diagnosis and new treatment
    Slingerland, Annabelle S.
    Nuboer, R.
    Hadders Algra, Mijna
    Hattersley, Andrew T.
    Bruining, G. Jan
    HORMONE RESEARCH, 2006, 65 : 15 - 15
  • [12] Neonatal diabetes -: The role of KCNJ11 (Kir6.2)
    Tammaro, Paolo
    CONGENITAL ENDOCRINOPATHIES: NEW INSIGHTS INTO ENDOCRINE DISEASES AND DIABETES, 2007, 11 : 70 - 82
  • [13] Time-dependent activation of KIR6.2/SUR2A channels but not KIR6.2/SUR1 channels in the presence of MgATP
    Song, DK
    Ashcroft, FM
    JOURNAL OF PHYSIOLOGY-LONDON, 2001, 533 : 118P - 119P
  • [14] Molecular basis of Kir6.2 mutations associated with neonatal diabetes or neonatal diabetes plus neurological features
    Proks, P
    Antcliff, JF
    Lippiat, J
    Gloyn, AL
    Hattersley, AT
    Ashcroft, FM
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (50) : 17539 - 17544
  • [15] Time-dependent activation of Kir6.2/SUR2A channels but not Kir6.2/SUR1 channels in the presence of ATP
    Ashcroft, FM
    Song, DK
    BIOPHYSICAL JOURNAL, 2001, 80 (01) : 626A - 626A
  • [16] Kir6.2 mutations search in patients with permanent neonatal diabetes from a Polish population
    Klupa, T
    Flanagan, S
    Nazim, J
    Ellard, S
    Ciechanowska, M
    Starzyk, J
    Sieradzki, J
    Hattersley, AT
    Malecki, MT
    DIABETOLOGIA, 2005, 48 : A112 - A113
  • [17] Kir6.2 mutations search in patients with permanent neonatal diabetes from a Polish population
    Malecki, MT
    Klupa, T
    Flanagan, S
    Nazim, J
    Ciechanowska, M
    Starzyk, J
    Hattersley, AT
    Sieradzki, J
    DIABETES, 2005, 54 : A275 - A275
  • [18] Mechanism of allosteric SUR1 Kir6.2 interaction
    Schwanstecher, M.
    Pieper, B.
    Beyer, M.
    Schulz, M.
    Schwanstecher, C.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2009, 379 : 34 - 34
  • [19] Screening of SUR 1 and Kir6.2 promoters for mutations in different types of type 2 diabetes.
    Gloyn, AL
    Hashim, Y
    Turner, RC
    DIABETOLOGIA, 1998, 41 : A108 - A108
  • [20] Frequency of SUR1 and KIR6.2 mutations associated with familial hyperinsulinism (HI)
    Nestorowicz, A
    Behn, P
    Glaser, B
    Wilson, BA
    Schoor, KP
    Landau, H
    Stanley, CA
    Thornton, PS
    Permutt, MA
    DIABETOLOGIA, 1997, 40 : 12 - 12